Stoke Therapeutics Reports Q1 Results with Positive Clinical Data for Zorevunersen
Stoke Therapeutics (NASDAQ:STOK) reported positive clinical data from its Phase 1/2a extension studies, showing meaningful cognitive and behavioral improvements in patients treated with zorevunersen. The company also announced progress on the Phase 3 EMPEROR trial enrollment expected to be completed by June 2026.